OSIMERTINIB for Prostate cancer: Side Effects & Safety Data
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
There are 9 adverse event reports in the FDA FAERS database where OSIMERTINIB was used for Prostate cancer.
Most Reported Side Effects for OSIMERTINIB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Death | 10,423 | 37.6% | 10,418 | 239 |
| Malignant neoplasm progression | 2,920 | 10.5% | 574 | 354 |
| Diarrhoea | 1,408 | 5.1% | 174 | 431 |
| Drug resistance | 1,026 | 3.7% | 139 | 98 |
| Fatigue | 819 | 3.0% | 102 | 231 |
| Rash | 772 | 2.8% | 79 | 212 |
| Decreased appetite | 706 | 2.5% | 138 | 273 |
| Drug ineffective | 627 | 2.3% | 144 | 111 |
| Dyspnoea | 621 | 2.2% | 158 | 327 |
| Nausea | 610 | 2.2% | 82 | 228 |
| Disease progression | 607 | 2.2% | 107 | 33 |
| Off label use | 576 | 2.1% | 115 | 124 |
| Interstitial lung disease | 573 | 2.1% | 221 | 305 |
| Metastases to central nervous system | 560 | 2.0% | 125 | 109 |
| Myelosuppression | 510 | 1.8% | 10 | 166 |
Other Indications for OSIMERTINIB
Non-small cell lung cancer (6,358)
Lung neoplasm malignant (4,754)
Lung carcinoma cell type unspecified stage 0 (1,950)
Non-small cell lung cancer metastatic (1,056)
Lung adenocarcinoma (936)
Egfr gene mutation (695)
Product used for unknown indication (408)
Non-small cell lung cancer stage iv (404)
Neoplasm malignant (345)
Lung carcinoma cell type unspecified stage iv (330)
Other Drugs Used for Prostate cancer
LEUPROLIDE (45,399)
ENZALUTAMIDE (25,954)
RELUGOLIX (18,752)
ABIRATERONE (12,209)
APALUTAMIDE (3,286)
GOSERELIN (2,080)
DEGARELIX (2,035)
BICALUTAMIDE (1,832)
SIPULEUCEL-T (1,720)
DENOSUMAB (1,627)